(GLOBE NEWSWIRE via COMTEX) –ObsEva SA / ObsEva Announces Upcoming Presentations Related to its Endometriosis and Uterine Fibroid Development Programs…
Category: Content
This category defines content that can be used throughout the website. So for example an article, a report, a file,… i.e. a press release can be displayed on the “press release” page but the newest press release is also displayed on the homepage.
Annual Report 2017
ObsEva-Annual-Report-2017 (2)Download
ObsEva SA to Host Key Opinion Leader Meeting on In Vitro Fertilization (IVF) April 26, 2018 in New York City
Geneva, Switzerland and Boston, MA – April 16, 2018 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development…
ObsEva SA to Participate in the H.C. Wainwright Annual Global Life Sciences Conference April 8-10, 2018
Geneva, Switzerland and Boston, MA – March 26, 2018– ObsEva SA (NASDAQ:OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for…
Effects of the Oral Prostaglandin F2 Alpha Receptor Antagonist Tocolytic OBE022 on Reproduction in Rats and Rabbits
Oliver Pohl, Roberta Sisti, Jean-Pierre Gotteland
SRI Conference, 06-10 March 2018, San Diego, CA
Abstract S-037: page 265A
Reproductive Sciences Vol. 25, Supplement 1, March 2018 265A Abstract S-037
Safety and Pharmacokinetics of the Oral Prostaglandin F2 Alpha Receptor Antagonist Tocolytic OBE022: A First-in-Human Study in Healthy Women
Oliver Pohl, Ulrike Lorch, Line Marchand, Jean-Pierre Gotteland
SRI Conference, 06-10 March 2018, San Diego, CA
Abstract S-038: Pages 265A-266A
Reproductive Sciences Vol. 25, Supplement 1, March 2018 265A-266A Abstract S-038
ObsEva Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Business Update
Pipeline Achievements in 2017 Included Progress with Three Phase 3 and Two Phase 2 Clinical Trials Key 2018 Clinical Milestones…
Q4 2017 ObsEva SA Earnings Conference Call
ObsEva SA to Hold Fourth Quarter and Year-end 2017 Financial Results and Business Update Call on March 9, 2018
Geneva, Switzerland and Boston, MA – March 2, 2018 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development…
ObsEva Announces Presentations Related to its Pre-term labor (PTL) Development Program at SRI 2018 Annual Meeting
Oral administration of OBE022 shows favorable safety and results in predictable exposureNon-clinical results of OBE022 for PTL demonstrating fetal safety…